ajax loader

Loading...


Ride-the-Wave Strategy – Best for Stock Traders

Ride-the-Wave targets multi-day price momentum following a company’s earnings announcement (EA). With this strategy:

  1. Buy a stock one day post-EA if a stock reacts positively post-earnings:
    1. Near the close of trading the EA-day for a pre-market-EA
    2. Near the close of the following day for a post-market-EA
  2. Sell-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Similarly,

  1. short a stock one day post-EA if a stock reacts negatively post-earnings:
    1. near the close of trading the EA-day for a premarket-EA
    2. near the close of the following day for a post-market-EA
  2. then buy-to-close after 7-10 days, or possibly earlier if a desired price target is reached

Important: Ride-the-Wave is predicated on significant price momentum triggered by an EA. The 7-10 day scenario is the maximum trade hold-time. If you see post EA-momentum is halted or reversed by a significant opposite move, re-evaluate your presence in the trade.

This popular StockEarnings screen below will give you a list of stocks that historically exhibit significant price momentum following an EA for the next seven days:

  1. Stocks exhibiting positive post-EA price moves are buy-candidates
  2. Stocks exhibiting negative post-EA price moves are sell/short-candidates

The screen includes those stocks whose Earnings just came out in last two days.

Screen criteria:

  1. Earnings Date Start Date : Current Date + -1 Day
  2. Earnings Date End Date : Current Date + -2 Days
  3. Predicted Move (Next Day) Max : 7%
  4. Predicted Move (On 7th Day) Min : 7%

Strategy Guideline:

  1. Buy the stock if stock has reacted positively. Short the stock if stock has reacted negatively (see above).
  2. Close the position in 7-10 days, or possibly earlier based on price move.

Volatility Crush Strategy - Best for Options Traders

The Volatility Crush strategy is used with stocks that typically experience relatively low-to-moderate price moves (≤4%) following their Earnings Announcements (EA). The basic trade idea is to sell put or call options right before the EA, collecting a credit when options premium is very high due to elevated implied volatility (IV). You then close the position right after the EA by buying the option back much cheaper due to the significant drop in IV that occurs after the mystery of the EA disappears. In assessing this trade, you need to do your homework to ensure you collect sufficient premium to make the trade worthwhile.

This trade is practical due to the low-to-moderate price-move after the EA, which generally won’t significantly affect the options price, unlike an “action” stock, which experience great price moves post-EA. With these symbols, if you’re on the right side of the price move, that’s a great thing. But if you’re on the wrong side of the move, not so great. Consequently, by minimizing the effect of the post-EA price move, you have a much better chance to profit from the reduction in IV without it being ruined by a violent price move.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

For this trade, open the position either (1) the night before the EA when the company announces earnings or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular stockearnings screen will give you a list of stocks which do not react more than 4% fpost-EA. It includes only those stocks whose earnings are releasing next day.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 1
  2. Earnings Date End Date : Current Date + 1
  3. Predicted Move (Next Day) Max : 4%
  4. Options Type: Weekly

Strategy Guideline:

  1. Options Strategy: Sell Call and Put
  2. Options Strike Price: Current Stock Price – (% Predicated Move x 2)
  3. Expiration Date: It should generally be the closest expiry immediately after the EA.
  4. Buy Insurance: Buying back Call and Put at Strike price which 10% lower than Sell Strike Price is optional but recommended.

Watch Video for More Detail

Volatility Rush Strategy - Best for Options Traders

The Volatility Rush takes advantage of increasing options premiums into earnings announcements (EA) caused by an anticipated rise in Implied Volatility (IV). With this strategy, Buy a Call and Put at-the-money (a long straddle) 2-3 weeks before the EA when IV is lower. Sell the position either (1) the night before the EA when the company announces earnings pre-market, or (2) during the EA day when it announces post-market, generally capturing IV at or close to its peak.

This popular screen will give you a list of stocks whose Options premiums tend to rise into Earnings. It includes only those stocks whose Earnings are at least two weeks away from today.

Screen criteria:

  1. Earnings Date Start Date : Current Date + 15 Days
  2. Earnings Date End Date : Current Date + 30 Days
  3. Predicted Move (Next Day) Min : 5%
  4. Options Type: Weekly or Monthly if that lines up with the two to three-week lead-time for entering the trade

Strategy Guideline:

  1. Buy a Straddle at or close to the money two to three weeks pre-EA.
  2. Sell the position either the night before the EA when the company announces earnings pre-market, or during the EA day when it announces post-market.
  3. Expiration date should generally be the closest expiry immediately after the EA.
  4. Straddle price should not be more 60% of predicted move.

Predicted Move (Volatility)

Similar to Implied Volatility in Options. Expected volatility % based on our Proprietary Volatility Predication Model. We are expecting that stock price will likely to reach % in either direction by the end of next trading session after Earnings are released and not necessarily the closing volatility %.

Why is it important?

    This indicator helps

  1. Knowing expected volatility in stocks after Earnings helps to decide trading stocks before Earnings Announcement.
  2. Taking Advantage of volatility collapse following Earnings Results by using Advance Options strategies such as Spread and Straddles.

Since Last Earnings

Change in share price since last Earnings release.

Why is it Important?

When share has gained more than 10% since it's last Earning release, it tends to over react to minor bad news and give up some gains if not all. So, it contains more downside volatility than upside When share has dropped more than 10% since it's last Earning release, it tends to over react to minor good news and recover some drops if not all. So, it contains more upside volatility than downside.

EPS Surprise (%)

Occurs when a company's reported quarterly or annual profits are above or below analysts' expectations. Here is the formula to derive % EPS Surprice:

Actual EPS - Estimated EPS
------------------------------------- x 100
Estimated EPS

Why is it Important?

Earnings surprises can have a huge impact on a company's stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock's price, but also to a gradual increase over time. Hence, it's not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.

Next Day Price Change (%)

Next Regular trading session Closing price following Earnings result.

For After Market Close Earnings, It is a next trading day closing price. For Before Market Open Earnings, It is the same trading day closing price.

Why is it Important?

Next Day price change is a reaction of Earnings result.

APTX MENU
APTX
CLOSE

Aptinyx Inc (APTX) News Today

Add to Watchlist (Why?)
Aptinyx Appoints Gilmore O
Aptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of Directors
October 20 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. “Gilmore brings an exceptional background of experience and leadership

Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference
September 20 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m. ET. A live webcast of the presentation will be available to view on the “Events and Presentations” page

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures
September 16 2021 03:37 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators. “Access to this capital provides us with additional f

Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
August 31 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Monday, September 13, 2021. A l

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript
August 10 2021 07:49 PM

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript

CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
August 10 2021 02:49 PM

EVANSTON, Ill.--(BUSINESS WIRE)--In the Condensed Balance Sheet, last line should read: Total liabilities and stockholders' equity   $ 134,168   $ 150,606 instead of: Total liabilities and stockholders' equity   $ 134,169   $ 150,606 The updated release reads: APTINYX REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS Enrollment on track in both Phase 2b chronic pain studies with NYX-2925—data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study

Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights
August 10 2021 01:10 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates. “We continue to make good progress in advancing our pipeline programs to enable multiple important Phase 2 data readouts in 2022,” said Norbert Riedel, PhD, chief executive officer of Aptinyx. “With several trans

Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
August 03 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the “Brains of the Operation - Novel Approaches in Neuro” panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10 at 12:00 p.m. ET. A live webcast of the presentation will be available t

Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
Aptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
July 26 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10, 2021 at 5:00 p.m. ET to report second quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (internat

Aptinyx: CNS Drug Discoverer With Depressed Price
Aptinyx: CNS Drug Discoverer With Depressed Price
July 21 2021 01:19 PM

APTX stock went into long-term depression following a failed trial in 2019.

Aptinyx to Participate in William Blair Biotech Focus Conference 2021
Aptinyx to Participate in William Blair Biotech Focus Conference 2021
July 12 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Updates in Neuropysch panel discussion at the William Blair Biotech Focus Conference on Thursday, July 15 at 12:00 p.m. ET. A live webcast of the presentation will be available to view on the “Events and Presentations”

Aptinyx Stock Looks Promising If You
Aptinyx Stock Looks Promising If You're Willing to Be Patient
July 12 2021 03:00 AM

When you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. APTX stock is looking good here.

Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
Aptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
July 06 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on Tuesday, July 13 at 3:40 p.m. ET. A live webcast of the event will be available to clients of Cowen. About Aptinyx Aptinyx Inc. is a clinical-stage biopharmaceutical

Aptinyx to Participate in Upcoming Investor Conferences
Aptinyx to Participate in Upcoming Investor Conferences
June 17 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the Company will be participating in two upcoming investor conferences: Oppenheimer Biotech by the Lake 2021 Investor Summit – Norbert Riedel, Ph.D., chief executive officer, will participate in the “Hot Topics in Neurological Disorder Therapeutics and Technologies” Panel discussion on Tue

Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients
Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients
June 16 2021 03:45 AM

After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program will consist of two separate studies to evaluate NYX-783 at two dose levels: 50 mg (Study 1) and 150 mg (Study 2).

APTX Stock Price Falls Over 10% Pre-Market: Why It Happened
APTX Stock Price Falls Over 10% Pre-Market: Why It Happened
June 16 2021 03:29 AM

The stock price of Aptinyx Inc. (Nasdaq: APTX) fell by over 10% pre-market. This is why it happened.

Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
June 15 2021 01:10 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD) after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA). The company expects to initiate the Phase 2b program in

Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?
Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?
June 11 2021 10:14 AM

Top growth penny stocks to watch this year? Check these 3 out right now The post Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2021 Results - Earnings Call Transcript
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2021 Results - Earnings Call Transcript
May 13 2021 08:10 PM

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q1 2021 Results - Earnings Call Transcript

Aptinyx Reports First Quarter 2021 Financial Results and Highlights
Aptinyx Reports First Quarter 2021 Financial Results and Highlights
May 13 2021 01:05 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2021 and highlighted recent progress across the company's pipeline of novel, clinical-stage, NMDA receptor modulators. “We have made excellent progress across our clinical-stage programs over the past few months,” said Norbert Riedel, Ph.D., chief execu

Aptinyx Appoints Joan W. Miller, M.D.
Aptinyx Appoints Joan W. Miller, M.D.
May 10 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachuse

Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
Aptinyx to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
April 29 2021 01:05 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 13, 2021 at 5:00 p.m. ET to report first quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (i

Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological Psychiatry Annual Meeting
Aptinyx Presents Additional Positive Data from Phase 2 Exploratory Study of NYX-783 in PTSD at Society of Biological Psychiatry Annual Meeting
April 29 2021 03:47 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder (PTSD) at the Society of Biological Psychiatry (SOBP) Annual Meeting being held virtually April 29 - May 1, 2021. The Phase 2 study evaluated NYX-783 in 153 patients with PTSD

Aptinyx to Participate in Upcoming Conferences
Aptinyx to Participate in Upcoming Conferences
April 27 2021 04:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences: 4th Annual Neuroscience Innovation Forum – Norbert Riedel, Ph.D., chief executive officer, will participate in the Pain & Addiction Panel discussion at 11:30 a.m. ET on April 29, 2021; and 7th Annual Truist Securi

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week
Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week
April 24 2021 10:22 AM

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Aptinyx Stock Price Increased Over 4% Pre-Market: Why It Happened
Aptinyx Stock Price Increased Over 4% Pre-Market: Why It Happened
April 06 2021 04:19 AM

The stock price of Aptinyx (NASDAQ: APTX) increased by over 4% pre-market. This is why it happened.

Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
April 06 2021 03:57 AM

Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies. Aptinyx will release the data from this study in the second half of 2022.

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson's Disease Dementia and Dementia with Lewy Bodies
April 06 2021 03:37 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022. “W

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2020 Results - Earnings Call Transcript
Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2020 Results - Earnings Call Transcript
March 24 2021 07:18 PM

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2020 Results - Earnings Call Transcript

Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates
Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates
March 24 2021 03:17 PM

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Aptinyx: Q4 Earnings Insights
Aptinyx: Q4 Earnings Insights
March 24 2021 02:45 PM

Shares of Aptinyx (NASDAQ:APTX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 51.22% year over year to ($0.20), which beat the estimate of ($0.24).

Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 24 2021 01:05 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2020 and provided updates across the company's pipeline of novel NMDA receptor modulators. “Despite the COVID-19 pandemic, we are excited to be advancing clinical development across all four of our pipeline programs,” said Norbert

Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week
Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
March 17 2021 10:38 AM

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
March 02 2021 06:31 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 24, 2021 at 5:00 p.m. ET to report fourth quarter and full year 2020 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or

Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference
Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference
February 11 2021 06:30 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST. A live webcast of the presentation will be available to view on the “Events and Presentations” page in the

Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions
Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions
January 19 2021 06:31 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel NMDA receptor modulator, NYX-2925. The data span across numerous preclinical models and highlight the potential therapeutic benefits of NYX-2925 in treating chronic, centralized pain c

Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
January 05 2021 06:37 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021. The fireside chat will be available on-demand through the H.C. Wainwright conference portal, beginning at 6:00 AM ET on Monday, January 11, 2021. A webc

Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
January 04 2021 05:57 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that in December it recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the United States. “We are pleas

Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference
Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 21 2020 06:30 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. Norbert Riedel, Ph.D., chief executive officer, is scheduled to present on Thursday, January 14, 2021 at 9:10 a.m. Eastern Time. A live webcast of the presentation will be available to view o

Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer
Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer
December 16 2020 06:30 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the company's current chief operating officer, to the role of president and chief operating officer, effective December 14, 2020. “We are thrilled to have Andy expand his role as president and chief operating officer, given his strong commitment to our co

Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript
Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript
November 12 2020 08:11 PM

Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript

Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights
Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights
November 12 2020 02:03 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2020 and highlighted recent progress across the company's clinical-stage pipeline of novel NMDA receptor modulators. “I am very pleased with the remarkable progress we have made over the past several months despite the negative impact of COVID

Aptinyx to Participate in Upcoming Virtual Investor Conferences
Aptinyx to Participate in Upcoming Virtual Investor Conferences
November 10 2020 06:37 AM

EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences: A presentation during the Stifel 2020 Virtual Healthcare Conference at 1:20 p.m. ET on Tuesday, November 17, 2020; and A pre-recorded fireside chat during the

Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020
Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020
October 29 2020 05:37 AM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, November 12, 2020 at 5:00 p.m. ET to report third quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-22

Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate
Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate
October 27 2020 10:35 AM

The market's skepticism around Aptinyx Inc's (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initiated coverage of Aptinyx with an Overweight rating and a price target of $10.

3 Top Healthcare Stocks Under $5
3 Top Healthcare Stocks Under $5
October 27 2020 04:00 AM

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option
October 26 2020 01:01 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 16,100,000 shares of its common stock, which included the exercise in full of the underwriters' option to purchase additional shares, at a public offering price of $3.00 per share. All of the shares sold in the offering were sold by Aptinyx. The g

Why Aptinyx Stock Sank Today
Why Aptinyx Stock Sank Today
October 21 2020 01:03 PM

Investors reacted negatively to the company's announcement of a secondary stock offering.

Aptinyx Announces Proposed Public Offering of Common Stock
Aptinyx Announces Proposed Public Offering of Common Stock
October 20 2020 01:01 PM

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares sold in the offering will be sold by Aptinyx. Aptinyx also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares t

Aptinyx News: Why APTX Stock Is Skyrocketing Today
Aptinyx News: Why APTX Stock Is Skyrocketing Today
October 20 2020 08:33 AM

APTX stock is soaring on Tuesday after Aptinyx announced very positive results from its trial for a treatment for those with PTSD. The post Aptinyx News: Why APTX Stock Is Skyrocketing Today appeared first on InvestorPlace.

Join over 100,000 investors who get daily notable Earnings alerts with predicted move.